WYE-687是一种ATP竞争性的，选择性的mTOR抑制剂，IC₅₀为7 nM；抑制mTORC1/pS6K(T389)和mTORC2/P-AKT(S473)，但不抑制P-AKT(T308)，作用于mTOR比作用于PI3Kα(>100倍)和PI3Kγ(>500倍)选择性高。

>98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO : 25 mg/mL (47.29 mM; ultrasonic and warming and heat to 60°C)

mTOR

Immune-complex kinase assay shows mTORC2-specific substrate His6-AKT or the mTORC1 substrate His6-S6K is dose dependently inhibited by WYE-687. WYE-687 globally inhibits mTOR signaling and AKT function in cellular models dose dependently. WYE-678 profoundly inhibits cap-dependent and global protein synthesis in MDA361, human breast cancer cells. WYE-687 shows antiproliferative effects in various cancer cell lines involving G1 cell cycle arrest and selective apoptosis. WYE-687 down-regulate angiogenic factors, VEGF and HIF-1α, in U87MG, MDA361 and LNCap cells.